Discovery of a potent phenolic N1-benzylidene- pyridinecarboxamidrazone selective against Gram-positive bacteria

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 4, 2006, Pages 879-883

  Rathbone, Daniel L ^a   Parker, Katy J ^a   Coleman, Michael D ^a   Lambert, Peter A ^a   Billington, David C ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Antimicrobial; Carboxamidrazone; MRSA

Indexed keywords

3,5 DI TERT BUTYL 2 HYDROXYBENZALDEHYDE; ANTIINFECTIVE AGENT; BENZALDEHYDE DERIVATIVE; DIMETHYL SULFOXIDE; ISONIAZID; N 1 [3,5 DI TERT BUTYL) 2 HYDROXYBENZYLIDENE] PYRIDINE 2 CARBOXAMIDRAZONE; N 1 BENZYLIDENE PYRIDINECARBOXAMIDRAZONE; PYRIDINE 4 CARBOXAMIDRAZONE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BORDETELLA BRONCHISEPTICA; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; HUMANS; LEUKOCYTES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

BORDETELLA BRONCHISEPTICA; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STENOTROPHOMONAS MALTOPHILIA;

EID: 30344481688     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.11.005     Document Type: Article

References (16)

1. M.G. Mamolo, L. Vio, E. Banfi, M. Predominanto, C. Fabris, and F. Asaro Farmaco 47 1992 1055
2. M.G. Mamolo, L. Vio, E. Banfi, M. Predominanto, C. Fabris, and F. Asaro Farmaco 48 1993 529
3. E. Banfi, M.G. Mamolo, L. Vio, and M. Predominanto J. Chemother. 5 1993 164
4. M.G. Mamolo, and L. Vio Farmaco 51 1996 65
5. D.C. Billington, P.R. Lowe, D.L. Rathbone, and C.H. Schwalbe Acta Crystallogr., Sect. C 56 2000 e211
6. D.C. Billington, M.D. Coleman, J. Ibiabuo, P.A. Lambert, D.L. Rathbone, and K.J. Tims Drug Des. Discov. 15 1998 269
7. M.G. Mamolo, and L. Vio Eur. J. Med. Chem. 21 1986 467
8. G. Casiraghi, G. Casnati, G. Puglia, G. Sartori, and G. Terenghi J. Chem. Soc., Perkin Trans. 1 1980 1862
9. +. Mp corrected: 156.7-158.0°C. CHN Analysis, % m/m (% calculated/% found): C, 71.56/71.70; H, 8.01/7.96; N, 15.89/16.01.
10. H. Onda, F.M. Wagenlehner, N. Lehn, and K.G. Naber Int. J. Antimicrob. Agents 18 2001 263
11. L. Collins, and S.G. Franzblau Antimicrob. Agents Chemother. 41 1997 1004
12. N. Gokhale, S. Padhye, D. Rathbone, D. Billington, P. Lowe, C. Schwalbe, and C. Newton Inorg. Chem. Commun. 4 2001 26
13. U. Sandbhor, S. Padhye, D. Billington, D. Rathbone, S. Franzblau, C.E. Anson, and A.K. Powell J. Inorg. Biochem. 90 2002 127
14. M.D. Coleman, D.L. Rathbone, L. Abberly, P.A. Lambert, and D.C. Billington Environ. Toxicol. Pharmacol. 7 1999 59
15. M.D. Coleman, D.L. Rathbone, C.R. Endersby, M.C. Hovey, K.J. Tims, P.A. Lambert, and D.C. Billington Environ. Toxicol. Pharmacol. 8 2000 167
16. M.D. Coleman, D.L. Rathbone, R. Chima, P.A. Lambert, and D.C. Billington Environ. Toxicol. Pharmacol. 9 2001 99